{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:34:31Z","timestamp":1778276071339,"version":"3.51.4"},"reference-count":53,"publisher":"Japan Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2007]]},"DOI":"10.1507\/endocrj.k07-126","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T05:49:39Z","timestamp":1198043379000},"page":"797-803","source":"Crossref","is-referenced-by-count":14,"title":["Toxic Thyroid Adenoma Presenting as Hypokalemic Periodic Paralysis"],"prefix":"10.1507","volume":"54","author":[{"given":"Tetsuya","family":"TAGAMI","sequence":"first","affiliation":[{"name":"Clinical Research Institute, Division of Endocrinology and Metabolism, Kyoto Medical Center, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"USUI","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Division of Endocrinology and Metabolism, Kyoto Medical Center, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"SHIMATSU","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Division of Endocrinology and Metabolism, Kyoto Medical Center, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhide","family":"NARUSE","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Division of Endocrinology and Metabolism, Kyoto Medical Center, National Hospital Organization"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ptacek LJ, Tawil R, Griggs RC, Engel AG, Layzer RB, Kwiecinski H, McManis PG, Santiago L, Moore M, Fouad G, Bradley P, Leppert MF (1994) Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 77: 863-868.","DOI":"10.1016\/0092-8674(94)90135-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Jurkat-Rott K, Lehmann-Horn F, Elbaz A, Heine R, Gregg RG, Hogan K, Powers PA, Lapie P, Vale-Santos JE, Weissenbach J, Fontaine B (1994) A calcium channel mutation causes hypokalemic periodic paralysis. Hum Mol Genet 3: 1415-1419.","DOI":"10.1093\/hmg\/3.8.1415"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Bulman DE, Scoggan KA, van Oene MD, Nicolle MW, Hahn AF, Tollar LL, Ebers GC (1999) A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 53: 1932-1936.","DOI":"10.1212\/WNL.53.9.1932"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Jurkat-Rott K, Mitrovic N, Hang C, Kouzmekine A, Iaizzo P, Herzog J, Lerche H, Nicolle SF, Vale-Santos JE, Chaurean D, Fontaine B, Lehmann-Horn F (2000) Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced activation and reduced current. Proc Natl Acad Sci USA 97: 9549-9554.","DOI":"10.1073\/pnas.97.17.9549"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Abott GW, Butler MH, Bendahhou S, Dalakas MC, Ptacek LJ, Goldstein SA (2001) MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell 104: 217-231.","DOI":"10.1016\/S0092-8674(01)00207-0"},{"key":"6","unstructured":"6. Fuhrer D, Krohn K, Paschke R (2005) Toxic adenoma and toxic multinodular goiter. In: Braverman LE, Utiger RD (eds) Werner &#38; Ingbar's The Thyroid, A fundamental and clinical text, 9 <sup>th<\/sup> ed. Lippincott Williams &#38; Wilkins, Philadelphia, 508-518."},{"key":"7","unstructured":"7. Davies TF, Larsen PR (2003) Thyrotoxicosis. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds) Williams textbook of Endocrinology, 10 <sup>th<\/sup> ed. Saunders, Philadelphia, 375-421."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365: 603-604.","DOI":"10.1038\/365649a0"},{"key":"9","unstructured":"9. Van Sande J, Parma J, Tonacchera M, Duprez L, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G (1995) Somatic and germline mutations of the TSH receptor gene in the thyroid diseases. J Clin Endocrinol Metab 80: 2577-2585."},{"key":"10","unstructured":"10. Tonacchera M, Agretti P, Chiovato L (2000) Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. J Clin Endocrinol Metab 85: 2570-2574."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Clapham DE (1993) Mutations in G protein-linked receptors: novel insights on disease. Cell 75: 1237-1239.","DOI":"10.1016\/0092-8674(93)90609-T"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dias da Silva MR, Cerutti JM, Tengan CH, Furuzawa GK, Vieira TCA, Gabbai AA, Maciel RMB (2002) Mutations linked to familial hypokalemic periodic paralysis in the calcium channel a1 subunit gene (Ca<sub>v<\/sub>1.1) are not associated with thyrotoxic hypokalemic periodic paralysis. Clin Endocrinol 56: 367-375.","DOI":"10.1046\/j.1365-2265.2002.01481.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kung AWC, Lau KS, Fong GCY, Chan V (2004) Association of novel single nucleotide polymorphisms in the calcium channel 1 subunit gene (Cav1.1) and thyrotoxic periodic paralysis. J Clin Endocrinol Metab 89: 1340-1345.","DOI":"10.1210\/jc.2003-030924"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tang NLS, Chow CC, Ko GTC, Tai MHL, Kwok R, Yao XQ, Cockram CS (2004) No mutation in the KCNE3 potassium channel gene in Chinese thyrotoxic hypokalaemic periodic paralysis patients. Clin Endocrinol 61: 109-112.","DOI":"10.1111\/j.1365-2265.2004.02079.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kelley DE, Gharib H, Kennedy FP, Duda RJ, McManis MB (1989) Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch Intern Med 149: 2597-2600.","DOI":"10.1001\/archinte.1989.00390110139031"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Norris Jr FH, Clark EC, Biglieri EG (1972) Studies in thyrotoxic periodic paralysis. Metabolic and ultrastructural studies. Arch Neurol Sci 13: 431-432.","DOI":"10.1016\/0022-510X(71)90005-0"},{"key":"17","unstructured":"17. Tinker TD, Vannatta JB (1987) Thyrotoxic hypokalemic periodic paralysis: report of four cases and review of the literature. J Okla State Med Assoc 80: 76-83."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Allings AM, Fliers E, de Herder WW, Hofland LJ, Sluiter HE, Links TP, van der Hoeven JH, Wiersinga WM (1998) A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis. J Endocrinol Invest 21: 703-706.","DOI":"10.1007\/BF03350802"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hsu FS, Tsai WS, Chau T, Chen HH, Chen YC, Lin SH (2003) Thyrotropin-secreting pituitary adenoma presenting as hypokalemic periodic paralysis. Am J Med Sci 325: 48-50.","DOI":"10.1097\/00000441-200301000-00011"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Okihiro MM, Nordyke RA (1966) Hypolkalemic periodic paralysis: experimental precipitation with sodium liothyronine. JAMA 198: 949-951.","DOI":"10.1001\/jama.1966.03110210199056"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tran HA (2005) Inadvertent iodine excess causing thyrotoxic hypokalemic periodic paralysis. Arch Intern Med 165: 2536.","DOI":"10.1001\/archinte.165.21.2536-a"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Akar S, Comlekci A, Birlik M, Onen F, Sari I, Gurler O, Bekis R, Akkoc N (2005) Thyrotoxic periodic paralysis in a Turkish male; the recurrence of the attack after radioiodine treatment. Endocr J 52: 149-151.","DOI":"10.1507\/endocrj.52.149"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Khan FA, Baron DN (1987) Ion flux and Na <sup>+<\/sup> , K <sup>+<\/sup> -ATPase activity of erythrocytes and leukocytes in thyroid disease. Clin Sci 72: 171-179.","DOI":"10.1042\/cs0720171"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lam KSL, Yeung RTT, Benson EA, Wang C (1989) Erythrocyte sodium-potassium pump in thyrotoxic periodic paralysis. Aust NZ J Med 19: 6-10.","DOI":"10.1111\/j.1445-5994.1989.tb01664.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chan A, Shinde R, Chow CC, Cockram CS, Swaminathan R (1991) In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. Br Med J 303: 1096-1099.","DOI":"10.1136\/bmj.303.6810.1096"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Lo CS, Edelman IS (1976) Effect of triiodothyronine on the synthesis and degradation of renal cortical Na K adenosine triphosphatase. J Biol Chem 251: 7834-7840.","DOI":"10.1016\/S0021-9258(19)57011-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Curfman GD, Crowley TJ, Smith TW (1977) Thyroid-induced alterations in myocardial sodium-potassium-activated adenosine triphosphatase, monovalent cation active transport, and cardiac glycoside binding. J Clin Invest 59: 586-590.","DOI":"10.1172\/JCI108675"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lin MH, Akera T (1978) Increased Na, K-ATPase concentrations in various tissues of rats caused by thyroid hormone treatment. J Biol Chem 253: 723-726.","DOI":"10.1016\/S0021-9258(17)38162-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Liberman UA, Asano Y, Lo CS, Edelman IS (1979) Relationship between Na dependent respiration and Na K-adenosine triphosphatase activity in the action of thyroid hormone on rat jejunal mucosa. Biophys J 27: 127-144.","DOI":"10.1016\/S0006-3495(79)85207-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Layzer RB (1982) Periodic paralysis and the sodium-potassium pump. Ann Neurol 11: 547-552.","DOI":"10.1002\/ana.410110602"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hundal HS, Marette A, Mitsumoto Y, Ramlal T, Blostein R, Klip A (1992) Insulin induces translocation of the 2 and 1 subunits of the Na <sup>+<\/sup> \/K <sup>+<\/sup> -ATPase from intracellular compartments to the plasma membrane in mammalian skeletal muscle. J Biol Chem 267: 5040-5043.","DOI":"10.1016\/S0021-9258(18)42725-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Blanco G, Mercer RW (1998) Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol 275: F633-F650.","DOI":"10.1152\/ajprenal.1998.275.5.F633"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pestov NB, Adams G, Shakhparonov MI, Modyanov NN (1999) Identification of a novel gene of the X, K-ATPase-subunit family that is predominantly expressed in skeletal and heart muscles. FEBS Lett 275: 243-248.","DOI":"10.1016\/S0014-5793(99)00954-0"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chaudhury S, Ismail-Beigi F, Gick GG, Lavenson R, Edelman IS (1987) Effect of thyroid hormone on the abundance of Na, K-adenosine triphosphatase-subunit messenger ribonucleic acid. Mol Endocrinol 1: 83-89.","DOI":"10.1210\/mend-1-1-83"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Desai-Yajinik V, Zeng J, Omorik, Sherman J, Morimoto T (1995) The effect of thyroid hormone treatment on the gene expression and enzyme activity of rat liver sodium potassium dependent adenosine triphosphatase. Endocrinology 136: 629-639.","DOI":"10.1210\/endo.136.2.7835297"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Wang W, Jiang L, Ye L, Zhu N, Su T, Guan L, Li X, Ning G (2006) Mutation screening in Chinese hypokalemic periodic paralysis patients. Mol Genet Metab 87: 359-363.","DOI":"10.1016\/j.ymgme.2005.10.020"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kung AWC, Lau KS, Cheung WMW, Chan V 2006 Thyrotoxic periodic paralysis and polymorphisms of sodium-potassium ATPase genes. Clin Endocrinol (Oxf) 64: 158-161.","DOI":"10.1111\/j.1365-2265.2005.02442.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kim TY, Song JY, Kim WB, Shong YK (2005) Arg16Gly polymorphism in 2-adrenergic receptor gene is not associated with thyrotoxic periodic paralysis in Korean male patients with Graves' disease. Clin Endocrinol (Oxf) 62: 585-589.","DOI":"10.1111\/j.1365-2265.2005.02264.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Fouad G, Dalakas M, Servidei S, Mendell JR, Van den Bergh P, Angelini C, Alderson K, Griggs RC, Tawil R, Gregg R, Hogan K, Powers PA, Weinberg N, Malonee W, Ptacek LJ (1997) Genotype-phenotype correlations of DHP receptor a1-subunit gene mutations causing hypokalemic periodic paralysis. Neuromusc Disor 7: 33-38.","DOI":"10.1016\/S0960-8966(96)00401-4"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Chen L, Lang D, Ran XW, Joncourt F, Gallati S, Burgunder JM (2003) Clinical and molecular analysis of Chinese patients with thyrotoxic periodic paralysis. Eur Neurol 49: 227-230.","DOI":"10.1159\/000070191"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ng WY, Lui KF, Thai AC, Cheah JS (2004) Absence of ion channels CACN1AS and SCN4A mutations in thyrotoxic hypokalemic periodic paralysis. Thyroid 14: 187-190.","DOI":"10.1089\/105072504773297858"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Lin S, Hsu Y, Cheng N, Kao M (2005) Skeletal muscle dihydropyridine-sensitive calcium channel (CACNA1S) gene mutations in Chinese patients with hypokalemic periodic paralysis. Am J Med Sci 329: 66-70.","DOI":"10.1097\/00000441-200502000-00003"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Wang W, Jiang L, Ye L, Zhu N, Su T, Guan L, Li X, Ning G (2006) Mutation screening in Chinese hypokalemic periodic paralysis patients. Mol Genet Metab 87: 359-363.","DOI":"10.1016\/j.ymgme.2005.10.020"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Tengan CH, De Oliveira AS, Gabbai AA (1994) Periodic paralysis: clinical analysis in 20 patients. Arq Neuropsiquiatr 52: 501-509.","DOI":"10.1590\/S0004-282X1994000400008"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Stenberg D, Tabti N, Fournier E, Hainque B, Fontaine B (2003) Lack of association of the potassium channel-associated peptide MiRP2-R83H variant with periodic paralysis. Neurology 61: 857-859.","DOI":"10.1212\/01.WNL.0000082392.66713.E3"},{"key":"46","unstructured":"46. Paschke R, Tonacchera M, Van Sande J, Parma J, Vassart G (1994) Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab 79: 1785-1789."},{"key":"47","unstructured":"47. Porcellini A, Ciullo I, Laviola L, Amabile G, Fenzi G, Avvedimento VE (1994) Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. Rapid identification by fine needle aspiration biopsy. J Clin Endocrinol Metab 79: 657-661."},{"key":"48","unstructured":"48. Parma J, Van Sande J, Swillens S, Tonacchera M, Dumont J &#38; Vassart G (1995) Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 30, 50-monophosphate and inositol phosphate-Ca <sup>2+<\/sup> cascades. Mol Endocrinol 9: 725-733."},{"key":"49","unstructured":"49. Russo D, Arturi F, Suarez HG, Schlumberger M, Du Villard JA, Crocetti U, <i>et al.<\/i> (1996) Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 81: 1548-1551."},{"key":"50","unstructured":"50. Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, <i>et al.<\/i> (1997) Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 82: 2695-2701."},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Tonacchera M, Cetani F, Parma J, Van Sande J, Vassart G, Dumont J (1996) Oncogenic mutations in thyroid adenoma: methodological criteria. Eur J Endocrinol 135: 444-446.","DOI":"10.1530\/eje.0.1350444"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Kosugi S, Hai N, Okamoto H, Sugawa H, Mori T (2000) A novel activating mutation in the thyrotropin receptor gene in an autonomously functioning thyroid nodule developed by a Japanese patient. Eur J Endocrinol 143: 471-477.","DOI":"10.1530\/eje.0.1430471"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Vanvooren V, Uchino S, Costa MJ, Vandekerckhove J, Parma J, Vassart G, Dumont JE, Van Sande J, Noguchi S (2002) Oncogenic mutations in the thyrotropin receptor of autonomous functioning thyroid nodules in the Japanese population. Eur J Endocrinol 147: 287-291.","DOI":"10.1530\/eje.0.1470287"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/5\/54_K07-126\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:08:31Z","timestamp":1630364911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/54\/5\/54_K07-126\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k07-126","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}